The CRLB-GMEL offers a full range of laboratory services including:
- Biochemistry & biomarker analysis
- Genomics including DNA sequencing, gene expression, epigenetics
Genetic Analysis Using Multi-Omics
The genetics and molecular epidemiology team at CRLB-GMEL provides a broad range of genomic and proteomic solutions:
- Specializing in large-scale population genetic studies, capable of handling project sizes ranging from single samples to >10,000 samples.
- Supporting experimental design considerations, bioinformatics and statistical analyses, and interpretation/reporting of results.
We offer flexible bioinformatics support for all genomic services with regards to:
- Experimental design and planning considerations
- Quality control
- Statistical analysis
- Results interpretation and reporting
- Methodological / analytical tool development and optimization
Featuring two genotyping platforms and a proteomics platform, and the use of DNA methylation and gene expression analysis, the laboratory has supported many landmark PHRI studies over the years, and plays a growing role in PHRI’s current and planned studies – include components of active genetic analysis.
The CRLB-GMEL laboratory was born as a new entity in late 2020, a combination of:
- The Clinical Research Laboratory (CRLB), established in 1987 at McMaster University to support clinical trials, biobanking, and biochemistry testing. One of its founders, Matthew McQueen, is today the Deputy Director, CRLB-GMEL.
- The Genetic and Molecular Epidemiology Laboratory (GMEL) was established in 2010, a collaboration between McMaster, PHRI, and TaARI. The GMEL conducts genetic testing, and researches new methods to conduct those tests.